Baird Downgrades Acorda Therapeutics, Inc. (ACOR) to Neutral; Ampyra Launch More Challenging than Expected
Tweet Send to a Friend
Baird downgraded Acorda Therapeutics, Inc. (NASDAQ: ACOR) from Outperform to Neutral. PT lowered from $40 to $31.
Baird analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
